Regeneron Pharmaceuticals Reports Q2 2025 Revenue of $3.68 Billion, Net Income Declines

Regeneron Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, revealing total revenues of $3.68 billion, a 3.6% increase from $3.55 billion in the same period of 2024. The company's net income for the quarter was $1.39 billion, or $12.81 per diluted share, compared to $1.43 billion, or $12.41 per diluted share, in the prior year. For the first half of 2025, Regeneron generated revenues of $6.70 billion, slightly up from $6.69 billion in the first half of 2024, while net income increased to $2.20 billion from $2.15 billion year-over-year.

A significant factor in Regeneron's financial performance was the decline in net product sales, which totaled $1.63 billion for the second quarter, down from $1.92 billion in the same quarter of 2024. The decrease was primarily attributed to lower sales volumes of EYLEA, which faced competitive pressures and a transition of patients to EYLEA HD, a higher-dose formulation. In contrast, collaboration revenue surged to $1.86 billion, up from $1.52 billion, driven by increased profits from the company's partnership with Sanofi, particularly for Dupixent.

Operationally, Regeneron has made strategic moves, including the acquisition of an FDA Rare Pediatric Disease Priority Review Voucher for $155 million and the initiation of a license agreement with Hansoh Pharmaceuticals for a dual GLP-1/GIP receptor agonist, HS-20094, which is currently in Phase 3 clinical development. The company also reported an increase in research and development expenses, which rose to $1.42 billion in the second quarter, reflecting ongoing investments in clinical trials and product development.

As of June 30, 2025, Regeneron had total assets of $38.22 billion, with cash and cash equivalents amounting to $1.99 billion. The company’s employee headcount increased to 15,207, up from 14,176 a year earlier, indicating growth in its operational capacity. Looking ahead, Regeneron anticipates continued fluctuations in its financial results, influenced by the commercialization of EYLEA HD, EYLEA, and Dupixent, as well as the ongoing development of its product pipeline. The company remains focused on advancing its research and development efforts while navigating competitive pressures in the biopharmaceutical market.